Skip to main content
Caplight Logo









NextRNA Therapeutics

NextRNA Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://nextrnatx.com

Last Round

Series A

Mar 1, 2022

Total Funding Raised

$56.1M

Company Overview

NextRNA Therapeutics is a biotechnology company that developed small molecule therapeutics targeting dysregulated long non-coding RNAs (lncRNAs) to treat diseases in oncology and neuroscience.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

long non-coding RNAlncRNAsmall molecule therapeuticsdrug discovery platformoncology therapeuticsundruggable targetsbiotech R&DRNA-targeted therapydrug discovery partnershipcomputational biologysmall molecule drugpreclinical biotechRNA drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NextRNA Therapeutics Comparables

Compare NextRNA Therapeutics with similar companies based on industry and business-model similarity.

NextRNA Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Arrakis Therapeutics
88%
Amaroq Therapeutics
86%
Expansion Therapeutics
84%

NextRNA Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 1, 2022
SeedMar 1, 2022

Key People

Founding team and executive leadership

Dominique Verhelle

Co-founder, President And CEO, Co-founder And CSO

Founding Team

NextRNA Therapeutics Investors

Notable investors and investment history

NextRNA Therapeutics investors
InvestorRounds
JefferiesSeed, Series A
Circle Squared Alternative InvestmentsSeries A
Evans CapitalSeed, Series A
Rivas CapitalSeed, Series A
Willett AdvisorsSeed, Series A
Cobro VenturesSeed, Series A
LightChain CapitalSeed, Series A

NextRNA Therapeutics Filings

Explore SEC and related filing metadata, where available.

NextRNA Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about NextRNA Therapeutics's valuation, stock price, and market status.

Is NextRNA Therapeutics a public or private company?

NextRNA Therapeutics is a private company.

What is the current stock price of NextRNA Therapeutics?

NextRNA Therapeutics is a private company, so its shares have no public market price. Caplight tracks NextRNA Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is NextRNA Therapeutics worth (valuation)?

Valuation information for NextRNA Therapeutics is not publicly available.

Can I buy NextRNA Therapeutics stock?

NextRNA Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was NextRNA Therapeutics's last funding round?

NextRNA Therapeutics's most recent funding round was Series A on March 1, 2022.

Who are the main investors in NextRNA Therapeutics?

Key investors in NextRNA Therapeutics include Cobro Ventures, LightChain Capital.

Will NextRNA Therapeutics IPO soon?

No public IPO plans have been announced for NextRNA Therapeutics.

How can I track NextRNA Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades in NextRNA Therapeutics's shares on secondary markets.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range7
Year Founded2021
Last FundingMar 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?